The results of phase - I of Oxford COVID-19 vaccine trial published on Monday. According to the United Kingdom-based medical journal The Lancet, the vaccine is effective. Richard Borton, the editor-in-chief of the journal, said, "it is safe, well-tolerated and immunogenic."